Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05337163Completed

A Multicenter Clinical Trial of Sputum DNA Testing for Lung Cancer in China

Role: lead

NCT05337189Recruiting

A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China

Role: lead

NCT04722055Completed

A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China

Role: lead

NCT05374369Completed

Retrospective Analysis of Colorectal Cancer Screening Results

Role: lead

All 4 trials loaded